A novel pill, daraxonrasib, nearly doubled survival for advanced pancreatic cancer patients to 13.2 months, blocking a mutated protein in 90% of cases. It offers fewer side effects, marking a major breakthrough for this deadly disease.
Experimental Pill Doubles Survival in Pancreatic Cancer
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →